Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire) - Feb 23, 2023 - "During 2023, the Company expects to accomplish the following key business objectives: (i) Expand clinical sites and make enrollment progress of the ReSPECT-GBM Phase 2b trial to support enrollment completion by the end of 2024; (ii) Publish ReSPECT-GBM Phase 1 data in a peer reviewed journal; (iii) Present safety and efficacy data from ReSPECT-GBM Phase 1/2a dose escalation trial and ReSPECT-GBM Phase 2b dose expansion trial in the second half of 2023."
P1 data • P1/2 data • Trial status • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|